Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Shield Therapeutics's pretax income for the
six
months ended in Dec. 2025 was €-6.63 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was €-14.76 Mil.
Shield Therapeutics's pretax margin was -27.48%.
During the past 12 years, Shield Therapeutics's highest Pretax Margin was -18.15%. The lowest was -5140.00%. And the median was -572.34%.
During the past 12 years, Shield Therapeutics's highest Pretax Margin was -18.15%. The lowest was -5140.00%. And the median was -572.34%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics Pre-Tax Income Related Terms
Shield Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1JS vs ZTS, UTHR, VTRS: Pre-Tax Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-14.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (FRA:1JS) has a Pre-Tax Income of €-14.76 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Pre-Tax Income too high?
Shield Therapeutics' current Pre-Tax Income is €-14.76 Mil.
How does Shield Therapeutics' Pre-Tax Income compare to ZTS and UTHR?
Shield Therapeutics' Pre-Tax Income of €-14.76 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Pre-Tax Income is €-14.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.04 — trading 65% below its estimated fair value. The current Pre-Tax Income is €-14.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Pre-Tax Income is €-14.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JS has been successfully added to your 
